Abstracts tagged "Lupus nephritis"

Abstract Number: 0261 • ACR Convergence 2020
Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study
Rosalba Santana-Flores¹, Anitha Ramu¹, Hana Rajevac² and Belinda Jim³, ¹Jacobi Medical Center at Albert Einstein College of Medicine, BRONX, NY, ²James J Peters Medical Center, NEW YORK, NY, ³Jacobi Medical Center at Albert Einstein College of Medicine, New Hyde Park, NY
Background/Purpose: Repeat renal biopsies are considered in patients with Lupus Nephritis (LN) flares or with failure of response to treatment. The influence of repeat renal…
Abstract Number: 0945 • ACR Convergence 2020
Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun², Lena Tanaka², James Kuchenbecker², Tomas Mustelin¹ and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Sensitivity to ultraviolet (UV) light affects up to 80% of SLE patients and can exacerbate systemic disease flares, including lupus nephritis (LN). Our findings…
Abstract Number: 1672 • ACR Convergence 2020
Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients
Najla Aljaberi¹, Arjun Mathur², Steffy Jose³, Theresa Hennard⁴, Angela Merritt¹, Qing Ma⁵, James Rose⁵, Rashmi Sahay⁶, Chunyan Liu⁶, Scott Wenderfer⁷ and Hermine I Brunner⁸, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁶Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ⁸PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall…
Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Michael Trevisonno¹, Alexander Hall¹, Cristina Sorrento¹ and Ellen M Ginzler², ¹State University of New York Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 0948 • ACR Convergence 2020
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Ricardo Grieshaber-Bouyer¹, Joshua Keegan², Peter Nigrovic³, James Lederer⁴ and Deepak Rao², ¹Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴BWH Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…
Abstract Number: 1673 • ACR Convergence 2020
Principles of Pediatric Lupus Nephritis in a Contemporary Multi-Center Cohort
Kathleen Vazzana¹, Ankana Daga², Beatrice Goilav³, Ekemini Ogbu⁴, Daryl Okamura⁵, Catherine Park⁶, Rebecca Sadun⁷, Emily Smitherman⁸, Brian Stotter⁹, Scott Wenderfer¹⁰ and Laura Lewandowski¹¹, ¹National Institute of Health/Children's National Hospital, Washington, DC, ²Harvard, Boston, MA, ³The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Seattle's Children's, Seattle, WA, ⁶Emory University, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Washington University School of Medicine, St. Louis, MO, ¹⁰Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹¹NIAMS, NIH, Rockville, MD
Background/Purpose: Lupus nephritis (LN) is a well-established and life-threatening manifestation of systemic lupus erythematosus (SLE) that is more common in children than adults. The demographics…
Abstract Number: 1833 • ACR Convergence 2020
Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) and vitamin D are both immunomodulators in SLE, but work through different mechanisms. Hydroxychloroquine has been proven to triple renal response to…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Peter Yorgin¹, Suhas Radhakrishna¹, Caitlin Carter¹, Johanna Chang¹, Katayoon Shayan¹, Lieuko Nguyen¹, Peter Chiraseveenuprapund¹ and Robert Sheets², ¹UCSD/Rady Children's Hospital, San Diego, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…
Abstract Number: 1836 • ACR Convergence 2020
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Zahir Amoura¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Dario Roccatello⁶, Richard Furie⁷, Thomas Schindler⁸, Jay Garg⁹, Matthew Cascino⁹, Brad Rovin¹⁰ and Andrea Doria¹¹, ¹Hôpital Pitié-Salpêtrière, Paris, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶S Giovanni Hospital, Univ of Turin, Turin, Italy, ⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰The Ohio State University, Columbus, ¹¹University of Padua, Padua, Italy
Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
Abstract Number: 0288 • ACR Convergence 2020
Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus
Sule Yavuz¹, Pascal Pucholt², Dag Leonard², Juliana Imgenberg-Kreuz², Matteo Bianchi², Johanna Sandling², Iva Gunnarsson³, Swedish Sle Network² and Lars Ronnblom², ¹Uppsala University Rheumatology, Doral, FL, ²Uppsala University, Uppsala, Sweden, ³Karolinska Institute, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is a common debilitating manifestation of Systemic Lupus Erythematosus (SLE). Despite improved understanding of underlying mechanisms driving to LN and early…
Abstract Number: 0979 • ACR Convergence 2020
The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW
Paul Hoover¹, Michael Peters², David Lieb³, Heather Geiger⁴, Rakesh Mishra⁵, Nir Hacohen² and Anne Davidson⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, ³Broad Institute, Boston, MA, ⁴New York Genome Center, New York, NY, ⁵Feinstein Institute, Manhasset, NY, ⁶Northwell Health, New York
Background/Purpose:Poor renal prognosis in lupus nephritis (LN) is associated with an abundance of renal macrophages and dendritic cells (DCs) but the role of these cells…
Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Verena Balbi¹, Clovis Silva², Tatiana Pedrosa³, Rosa Pereira³, Lucia Campos³, Elaine Leon³, Nilo Duarte³, Valdemir Carvalho⁴, Sandra Pasoto³, Debora Rosario³, Leticia Brandao³, Eloisa Bonfa³ and Nadia Aikawa³, ¹Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, ²Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].